Safinamide Mesylate

Safinamide Mesylate (CAS 202825-46-5) is a pharmaceutical-grade active pharmaceutical ingredient manufactured directly by Brother Enterprises Holding Co., Ltd., with samples available and compliance with ChP, USP, BP, EP, JP, IP, and Ph.Int. standards. It is a third-generation new chemical entity MAO-B inhibitor for Parkinson's disease used to extend levodopa's therapeutic effect by reducing degradation of already-secreted dopamine, helping maintain dopamine concentration in the brain; it is sold across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.